Peter Keil

Alvogen Korea Co., Ltd. engages in the manufacture of pharmaceutical products. It offers products for the therapeutic areas of endocrine system, urinary system, neuropsychiatry system, anti-inflammatory, antipyretic, analgesic, gastrointestinal system, cardiovascular system, dermatology, hepatitis, antibiotics, respiratory system, hormones etc. It provides pharmaceutical products in various dosage forms, including tablets, capsules, granules, powders, ampoules, vials and intravenous (IV) solutions. The company was founded on January 7, 1958 and is headquartered in Seoul, South Korea.

Alvogen Korea Holdings Ltd. is a holding company, which engages in the development and manufacture of pharmaceutical products. Its products include medicine for urogenital system, circulatory system, diabetes, digestive system, nephrology division, dermatological division, respiratory system, antibiotics, hormone drug, health supplements, and pain reliever. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Alvogen, Inc. develops, manufactures, and distributes generic pharmaceutical products. The firm's business include product development, contract manufacturing and research, sales of generic medicines, bio-similar, and over the counters. Its product portfolio consists of molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. The company was founded by Robert Wessman in 2009 and is headquartered in Pine Brook, NJ.